Greater Cannabis Company Announces Expansion Into CBD Cosmetics And Beauty Market
BALTIMORE, MD, April 09, 2019 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced its expansion into the cannabidiol (CBD) beauty, cosmetics and self-care markets. In addition to its highly bioavailable, orally dissolving transmucosal patch, the Company is now formulating and commercializing a new line of products for CBD-infused cosmetics and skincare applications.
Consumer demand for CBD-infused beauty products has prompted major retailers such as Walgreens, Sephora and CVS, and major cosmetic brands like Estee Lauder, to move into this emerging sector
said Aitan Zacharin, Chief Executive Officer of Greater Cannabis Company.
Our unique and proven technology coupled with the high stability of our product formulations well positions us to meet the market’s demand for CBD-infused beauty and cosmetic products
Led by an experienced team of executives and scientists, GCANRx has developed a licensed, patented technology platform that has demonstrated high bioavailability and stability in the delivery of cannabis actives across different mediums in lab studies. The Company combines this with expertise and innovation in concept development to full-scale commercialization. Its expertise, technology and product formulations can be utilized across a variety of industries, including beauty, cosmetics and many others.
CBD has a broad range of benefits in topical application, including antioxidants for anti-aging, anti-inflammatory for acne and more
But bioavailability and stability are enormously important to its effectiveness, which is our significant competitive advantage
concluded Mr. Zacharin.
GCANRx expanded to the cosmetic market in response to increasing request from potential clients. The Company expects to disclose new partnership and licensing agreements relating to this latest corporate development in the coming months. For additional more information on GCANRx, please visit www.gcanrx.com.
About The Greater Cannabis Company:
The Greater Cannabis is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The delivery system is versatile in that consumers and patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release. Greater Cannabis’ mission is to bring its technology to the global market through partnerships with leading cannabis, consumer products, and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.
Disclaimer: GCANRx relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.